Extended Data Fig. 4: Levels of cytokines in the PB of patients following treatment with CAR19/IL-15 NK cells.
Bar graphs showing the levels of cytokines (markers of cytokine release syndrome in (a), and effector cytokines in (b) in the PB of patients at baseline and the maximum values in the first 6 weeks or at 3 months or later after CAR19/IL-15 NK-cell infusion. (a) IL-1β (left), and IL-6 (right) (n = 33). (b) IL-15 (left), IFN-γ (middle), TNF-α (right) (n = 34). (c) Spider plot showing B cell counts calculated based on CD19+ B-cell frequencies by flow cytometry in PB samples collected from patients at baseline and at multiple timepoints post CAR-NK cell infusion (n = 37 patients). The dotted line represents the threshold for B-cell lymphopenia (<100 B-cells/μL). The shadowed area represents B-cell aplasia (<1 B-cell/μL). The solid blue line represents the mean. (d) Spider plot showing CD3+ T cell counts calculated based on flow cytometry in PB samples from patients at baseline and at multiple timepoints post CAR-NK cell infusion (n = 37 patients). The solid green line represents the mean. For panels a, b, each symbol represents an individual patient, data are shown as mean + s.e.m. P-values were determined by Kruskal-Wallis test in panels a, b. Each symbol represents an individual patient; outliers are identified as black dots.
